{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56"}]}],"title":"Treatment Failure/Progressive Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"17"}]}],"title":"Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"title":"Complete Response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"83"}],"units":"Participants"}],"description":"Best response to study treatment as defined by protocol-specific response criteria:\n\nComplete Response (CR) = absence of urine and serum M-components by immunofixation; bone marrow should be adequately cellular (\\>20%) with \\<1% monoclonal plasma cells by DNA-clg flow cytometry; serum calcium level must be normal; no new bone lesions nor enlargement of existing lesions; Normalization of serum concentrations of normal immunoglobulins is not required for CR. Partial Response (PR) = Reduction by \\> 75% in serum myeloma protein production; Decrease in monoclonal marrow plasmacytosis to \\<5%; Decrease in Bence-Jones proteinuria by \\>90%; No new lytic bone lesions or soft tissue plasmacytoma.\n\nTreatment Failures/Progressive Disease (PD) = Such patients do not fulfill the above criteria and/or have new lytic lesions (but not compression fractures), hypercalcemia, or other new manifestations of disease.","groups":[{"description":"200 mg/day Thalidomide + 90 mg Pamidronate OR 4 mg Zometa every 2 weeks for 2 months and then every 4 weeks as maintenance therapy","id":"OG000","title":"Thalidomide + Bisphosphonate"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"2 years","title":"Best Response","type":"PRIMARY","unitOfMeasure":"participants"}